(Q62178506)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Kumlesh K. Dev

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Gaelle Elain

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Karine Jeanneau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Anis K Mir

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

1 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

725-735

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Treating multiple sclerosis with monoclonal antibodies: a 2013 update

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Immune function of astrocytes

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin-17 in transverse myelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Physiological and pathological roles of interleukin-6 in the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Gp130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Cellular mechanisms of IL-17-induced blood-brain barrier disruption

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Production and functions of IL-17 in microglia

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Retinal Astrocytes respond to IL-17 differently than Retinal Pigment Epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

IL-6: regulator of Treg/Th17 balance

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin 27 induces differentiation of neural C6-precursor cells into astrocytes.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

TLR2 deficiency leads to increased Th17 infiltrates in experimental brain abscesses

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

IL-17 enhancement of the IL-6 signaling cascade in astrocytes

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Regulation of CCL20 expression in astrocytes by IL-6 and IL-17

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Astrocytes stimulate interleukin-17 and interferon-γ production in vitro

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokin

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Increase of CD4+TNF{alpha}+IL-2-T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Interleukin-17: a mediator of inflammatory responses.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Metalloproteinases in biology and pathology of the nervous system.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22637

7 January 2021

Identifiers

DOI

10.1002/GLIA.22637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24677511%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference